Aladdin

Peresolimab (anti-PD-1) 是一种靶向 PD-1 的人源化 IgG1-κ 抗体。Peresolimab (anti-PD-1) 可能刺激生理免疫抑制途径，以恢复免疫稳态。62、英文描述： Peresolimab (anti-PD-1) is a humanized IgG1-κ antibody targeting to PD-1. Peresolimab (anti-PD-1) potentially stimulates physiological immune

Peresolimab (anti-PD-1) 是一种靶向 PD-1 的人源化 IgG1-κ 抗体。Peresolimab (anti-PD-1) 可能刺激生理免疫抑制途径，以恢复免疫稳态。62、英文描述： Peresolimab (anti-PD-1) is a humanized IgG1-κ antibody targeting to PD-1. Peresolimab (anti-PD-1) potentially stimulates physiological immune

Peresolimab (anti-PD-1) 是一种靶向 PD-1 的人源化 IgG1-κ 抗体。Peresolimab (anti-PD-1) 可能刺激生理免疫抑制途径，以恢复免疫稳态。62、英文描述： Peresolimab (anti-PD-1) is a humanized IgG1-κ antibody targeting to PD-1. Peresolimab (anti-PD-1) potentially stimulates physiological immune

Peresolimab (anti-PD-1) 是一种靶向 PD-1 的人源化 IgG1-κ 抗体。Peresolimab (anti-PD-1) 可能刺激生理免疫抑制途径，以恢复免疫稳态。62、英文描述： Peresolimab (anti-PD-1) is a humanized IgG1-κ antibody targeting to PD-1. Peresolimab (anti-PD-1) potentially stimulates physiological immune

Visugromab (anti-GDF15) is a GDF-15 neutralizing IgG4 mAb. Visugromab (anti-GDF15) exhibits potent effecicacy in PD-1/PD-L1 relapsed/refractory metastatic solid tumors.Purity≥95% (SDS-PAGE&amp:SEC)Endotoxin Level≤1.0EU/mg.

Visugromab (anti-GDF15) is a GDF-15 neutralizing IgG4 mAb. Visugromab (anti-GDF15) exhibits potent effecicacy in PD-1/PD-L1 relapsed/refractory metastatic solid tumors.Purity≥95% (SDS-PAGE&amp:SEC)Endotoxin Level≤1.0EU/mg.

Visugromab (anti-GDF15) is a GDF-15 neutralizing IgG4 mAb. Visugromab (anti-GDF15) exhibits potent effecicacy in PD-1/PD-L1 relapsed/refractory metastatic solid tumors.Purity≥95% (SDS-PAGE&amp:SEC)Endotoxin Level≤1.0EU/mg.

Visugromab (anti-GDF15) is a GDF-15 neutralizing IgG4 mAb. Visugromab (anti-GDF15) exhibits potent effecicacy in PD-1/PD-L1 relapsed/refractory metastatic solid tumors.Purity≥95% (SDS-PAGE&amp:SEC)Endotoxin Level≤1.0EU/mg.

Ezabenlimab (anti-PD-1) is an anti-PD-1 mAb with binding constant Kd value of 6 nM (CHO cells). Ezabenlimab (anti-PD-1) blocks the interaction of PD-1 with PD-L1 and PD-L2. Ezabenlimab (anti-PD-1) increases interferon-γ secretion in T cells, and

Ezabenlimab (anti-PD-1) is an anti-PD-1 mAb with binding constant Kd value of 6 nM (CHO cells). Ezabenlimab (anti-PD-1) blocks the interaction of PD-1 with PD-L1 and PD-L2. Ezabenlimab (anti-PD-1) increases interferon-γ secretion in T cells, and

Ezabenlimab (anti-PD-1) is an anti-PD-1 mAb with binding constant Kd value of 6 nM (CHO cells). Ezabenlimab (anti-PD-1) blocks the interaction of PD-1 with PD-L1 and PD-L2. Ezabenlimab (anti-PD-1) increases interferon-γ secretion in T cells, and

Ezabenlimab (anti-PD-1) is an anti-PD-1 mAb with binding constant Kd value of 6 nM (CHO cells). Ezabenlimab (anti-PD-1) blocks the interaction of PD-1 with PD-L1 and PD-L2. Ezabenlimab (anti-PD-1) increases interferon-γ secretion in T cells, and